- Home
- ANNX vs EOSE Comparison
ANNX vs EOSE Comparison
Compare ANNX & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- EOSE
- Stock Information
- Founded
- ANNX 2011
- EOSE 2008
- Country
- ANNX United States
- EOSE United States
- Employees
- ANNX N/A
- EOSE N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- EOSE Industrial Machinery/Components
- Sector
- ANNX Health Care
- EOSE Miscellaneous
- Exchange
- ANNX Nasdaq
- EOSE Nasdaq
- Market Cap
- ANNX 668.8M
- EOSE 542.2M
- IPO Year
- ANNX 2020
- EOSE N/A
- Fundamental
- Price
- ANNX $5.14
- EOSE $2.70
- Analyst Decision
- ANNX Strong Buy
- EOSE Strong Buy
- Analyst Count
- ANNX 7
- EOSE 6
- Target Price
- ANNX $15.80
- EOSE $5.42
- AVG Volume (30 Days)
- ANNX 1.4M
- EOSE 7.8M
- Earning Date
- ANNX 11-14-2024
- EOSE 11-05-2024
- Dividend Yield
- ANNX N/A
- EOSE N/A
- EPS Growth
- ANNX N/A
- EOSE N/A
- EPS
- ANNX N/A
- EOSE N/A
- Revenue
- ANNX N/A
- EOSE $14,963,000.00
- Revenue This Year
- ANNX N/A
- EOSE $187.90
- Revenue Next Year
- ANNX N/A
- EOSE $391.53
- P/E Ratio
- ANNX N/A
- EOSE N/A
- Revenue Growth
- ANNX N/A
- EOSE 20.34
- 52 Week Low
- ANNX $2.27
- EOSE $0.61
- 52 Week High
- ANNX $8.40
- EOSE $3.66
- Technical
- Relative Strength Index (RSI)
- ANNX 20.42
- EOSE 50.80
- Support Level
- ANNX $5.05
- EOSE $2.06
- Resistance Level
- ANNX $7.63
- EOSE $2.36
- Average True Range (ATR)
- ANNX 0.37
- EOSE 0.24
- MACD
- ANNX -0.23
- EOSE -0.01
- Stochastic Oscillator
- ANNX 3.68
- EOSE 56.14
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.